R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Oncology - Discovery (205)

Modality Indication Targets Stage Company Project No. Detail
1 Development of a First-in-Class MSLN x GAS6 Trap Bispecific ADC Candidate for Pancreatic Cancer: Overcoming Antigen Shedding and Remodeling Tumor Microenvironment
Antibody PDAC MSLN & TAM Hit Seoul National University RS-2026-25503246
2 Development of Orally Available Small-Molecule Hit and Lead Compounds for Immuno-Oncology via Inhibition of the CD73-Adenosine Axis and Enhancement of Antitumor Immune Activation
Small molecules Immune checkpoint inhibitor-resistant cancers CD73 Hit Gwangju Institute of Science and Technology RS-2026-25502995
3 Development of a biopharmaceutical lead molecule for the treatment of EGFR-positive cancer using an innovative modality that targets tumor surface EGFR and intracellular oncoprotein CP2c
Antibody HNSCC, CRC, TNBC EGFR / CP2c Hit Konkuk University GLOCAL Industry-Academic Cooperation Foundation RS-2026-25502354
4 Development of Lead Compounds for Pancreatic Cancer Targeting GSPT1 and ZFP91 via a Molecular Glue Based Next-Generation Protein Degradation Strategy
TPD PDAC GSPT1, ZFP91 Hit CoBX Bio Inc. RS-2026-25502077
5 Development of mRNA/LNP-Based Bio-PROTAC Platform Targeting pan-RAS for Lung Cancer Therapy
Gene & Nucleic acids AML/ALL CDK6 Hit Korea Institute of Science and Technology RS-2025-25452986
6 Indentification of lead CDK6-KLHDC2 PROTAC molecules and technology transfer
TPD AML/ALL CDK6 Hit Yonsei University University-Industry Foundation RS-2025-25452139
7 Discovery of first-in-class small molecule ***** inhibitors for treatment of RCC
Small molecules RCC ***** Hit Sogang University RS-2025-25452008
8 Development of In vivo CAR T using T cell specific Lentivirus
Gene & Nucleic acids Cancer/Immune disease T cell Hit Korea Research Institute of Chemical Technology RS-2025-02223194
9 Development of TEAD Interface3 Targeting Protein Degrader
TPD NF2-mutated cancer TEAD Hit Korea Research Institute of Chemical Technology RS-2025-02223174
10 Development of Self-Assembling Peptide-Based PROTAC Nanodrug for Overcoming Drug Resistance to EGFR Inhibitors
TPD Colon cancer, Head & neck cancer, NSCLC EGFR Hit Ewha Womans University RS-2025-02223093
11 EGFR-Targeted p53 mRNA-Based Head and Neck Cancer Therapy
Gene & Nucleic acids EGFR (+) Head and Neck cancer p53 Hit Sungkyunkwan University(Research Business Foundation) RS-2025-02213480
12 Development of EGFR specific BiTE (bispecific T cell engager) for solid tumor treatment
Antibody EGFR high expressing cancer EGFR, CD3 Hit SNU R&DB Foundation RS-2025-02172968
13 Development of treatment for drug-resistant cancer patients at the stage 4
Small molecules lung cancer, Colon cancer APE1 Hit KAIST RS-2024-00463605
14 Recurring and metastatic colorectal cancer New drug-targeted biomarker HSPA1L-METTL21A Protein-Protein Interactions (PPIs) Development of a New Lead
Small molecules Metastatic colorectal cancer N/A Hit Chosun University School of Medicine RS-2024-00463393
15 Discovery of SHMT2 inhibitors for the treatment of anaplastic thyroid cancers
Small molecules Anaplastic Thyroid Cancer SHMT2 (serine hyroxymethyltransferase 2) Hit Korea Research Institute of Chemical Technology RS-2024-00460989
16 Discovery of first-in-Class WNK3 targeted selective inhibitor for cancer immunotherapy
Small molecules Glioblastoma, Liver cancer WNK3 Hit Checkmate Therapeutics Inc. RS-2024-00337810
17 Development of First-in-Class NK Cell Engagers Targeting Trop2NKp46 Incorporating ADCC Maximizing Fc Variants for the Treatment of Triple-Negative Breast Cancer
Antibody TNBC Trop-2, NKp46, CD16A Hit Korea University RS-2024-00337233
18 The development of MAST3 inhibitor for anticancer drug
Small molecules Gastric cancer, Colon cancer MAST3 Hit Korea Reserch Institute Of Chemical Technology(KRICT) RS-2024-00336646
19 Discovery of selective first-in-class hit and lead compound targeting novel anti-cancer target SLC1A5_var against malignant tumor
Small molecules incurable cancer SLC1A5_var Hit Yonsei University RS-2024-00334337
20 Development of Lead compound of personalized therapeutic mRNA cancer vaccine by predicting the binding of tumor.reactive T cells and neoantigens
Gene & Nucleic acids Solid Tumor Tumor specific neoantigens predicted by a GENINUS platform based on binding affinity between TCR an Hit GENINUS INC. RS-2023-00284167
21 Discovery of VRK1 inhibitor for precision medicine of advanced/ refractory solid cancer
TPD Solid Tumor VRK1 Hit Korea Reserch Institute Of Chemical Technology(KRICT) RS-2023-00283832
22 Development of lead immunotherapy agent for cancer using IL.36 receptor agonist antibody
Antibody Melanoma IL.36 Hit Daegu Gyeongbuk Institute of Science & Technology(DGIST) RS-2023-00283446
23 IL.21 on/off switch.armored solid tumor.targeting TET KO CAR.T cell therapy
Cell therapies Solid Tumor IL.21 Hit Seoul National University RS-2023-00282907
24 Development of tumor ECM.modifying bispecific antibody for cancer immunotherapy
Antibody TNBC, NSCLC, PC DDR1, TGF.β Hit POSTECH RS-2023-00258678
25 Development of mRNA.encoded NK cell engager for the treatment of relapsed/refractory B cell lymphoma
Gene & Nucleic acids B cell lymphoma NK cell Hit De novo Biotherapeutics RS-2023-00258675
26 Structure based drug discovery of FOXM1 inhibitor for malignant tumor therapy
Small molecules Malignant tumor FOXM1 Hit Korea University College of Medicine RS-2022-00167112
27 Discovery of STING allosteric activator targeting non-T cell inflamed tumor
Small molecules Solid Tumor STING Hit Korea Institute of Science and Technology RS-2022-00166522
28 Development of a new therapeutic agent for bone metastasis cancer through the development of anti-****** humanized antibody
Antibody Solid Tumor CXCL16 Hit Cellus RS-2022-00166371
29 Development of hit/lead antibody neutralizing TMPRSS4, a novel therapeutic target for the treatment of non-small cell lung cancer
Antibody NSCLC TMPRSS4 Hit Korea Research Institute of Bioscience and Biotech RS-2022-00166100
30 Development of therapeutic autologous vaccine against acute myeloid leukemia
Other-Bio. AML αGC-loaded ECNV of AML Hit Seoul National University RS-2022-00165569
31 Development of macrophage-targeted clodronate-glycosylated albumin complex 
to inhibit tumor growth
rProtein Malignant tumor Macrophage Hit Seoul National University HN22C0644
32 Development of dual-functional hit/lead compounds targeting N3, a regulator of KRAS stability for the treatment of pancreatic cancer
Small molecules Pancreatic cancer NDRG3 Hit Korea Research Institute of Bioscience and Biotech HN22C0638
33 Discovery of Translocator Protein Targeting Cancer Therapeutics as effective substances
Small molecules Glioblastoma TSPO Hit Seoul National University HN22C0632
34 Development of tumor-derived exosome rupture peptide for combinational immunotherapy of colorectal cancer
rProtein Colorectal cancer Phopholipid layer Hit Sungkyunkwan University HN22C0624
35 Development of ALCAM aptamer-based ApDC anticancer drug
Gene & Nucleic acids Ovary cancer ALCAM Hit HiCELL Tech HN22C0558
36 Development of CD47/CD73 dual-target SAFAbody antibody therapy for the treatment of intractable solid cancer including triple-negative breast cancer
Antibody TNBC CD47, CD73 Hit AprilBio HN22C0297
37 Discovery of novel nucleic acid-sensing pathway modulators for the TNBC treatment
Small molecules TNBC ENPP1 Hit Korea Institute of Science and Technology HN22C0063
38 Development of complement C4d X CD3 BiTE
Antibody Cancer C4d, CD3 Hit Seoul National University HN22C0061
39 Development and optimization of a new form factor for next-generation cancer immunotherapy
Other-Bio. Solid Tumor DCs Hit Yonsei University HN21C1410
40 A study on development of lead antibodies targeting an immune checkpoint inhibitor refractory factor for metastatic melanoma
Antibody Metastatic malignant melanoma Oncokine-2 Hit Korea university HN21C0486
41 Hit and lead compound discovery of antibody-drug conjugate (ADC) targeting Doppel, a tumor-specific molecule
Antibody Cancer Doppel Hit Seoul National University HN21C0264
42 Development of lead compounds for solid tumor-targeting CC12 platform-based reinforced B7H3 CAR-T cells
Cell therapies Solid Tumor B7-H3, IL-12 Hit Seoul National University HN21C0232
43 Development of CAR T cell safety system using chemical switch
Cell therapies Blood Cancer CAR-DEGRON-T Hit KRICT(Korea Research Institute of Chemical Technology) HN21C0226
44 Development of antibody-based therapeutics neutralizing a novel target for the treatment of metastatic colorectal cancer
Antibody Metastatic colorectal cancer CCSP-2 Hit ASAN Medical Center HN21C0207
45 Development of ***** Targeted New Drug Lead Compounds Activating IFN-γ for Immune Checkpoint Inhibitor Resistant Cancers
Small molecules Cancer TPST2 Hit GIST(Gwangju Institute of Science & Technology) HN21C0196
46 Development of hit and lead asymmetric anti-CD20xCD55 bispecific antibodies containing Fc variants with maximized serum half-lives and effector functions for cancer therapy
Antibody Non-Hodgkin lymphoma, CLL CD20, CD55 Hit Korea University HN21C0103
47 Development of ‘Best-in-Class’ IL-2 for Solid Tumor Treatments
rProtein Kidney cancer, Skin cancer IL-2 Hit Genuv HN21C1125
48 Development of anti-PD-L1 x anti-SIRPα bispecific antibody that systemically activates both innate and adaptive anti-tumor immune system
Antibody Solid Tumor PD-L1, SIRPα Hit PharmAbcine Inc. HN21C0973
49 Development of a Lead Compound Targeting RNA Methyltransferase METTL3 for Cancer Immunotherapy
Small molecules Solid tumor (CRC) METTL3 Lead K-MEDI hub RS-2026-25503723
50 Lead Discovery: Dual-Mechanism Protein Therapy for Inflammatory Control and 'Cold-to-Hot' Tumor Conversion
rProtein CRC(colorectal Cancer) **** Lead Korea Research Institute of Bioscience and Biotechnology(KRIBB) RS-2026-25503253
51 Advancing in vivo CAR technology based on recombinant proteins for the treatment of CD19 B-cell blood cancers
rProtein CD19 positive B cell blood cancer CD19 Lead Kangwon National University RS-2026-25503120
52 Development of a Next-Generation Trop2-Targeted Aptamer–Drug Conjugate (ApDC) for Pancreatic Cancer and Solid Tumors
Gene & Nucleic acids Pancreatic cancer, Trop2-positive solid tumor Trop2 Lead APTAMER SCIENCES, Inc. RS-2026-25502769
53 Discovery of Next-Generation Menin Inhibitor/Degrader Lead Compounds to Overcome Acquired Resistance Mutations
Small molecules AML Menin Lead CoBX Bio., Ltd. RS-2026-25501934
54 Development of a Lead Candidate for an Antigen-Presenting Cell-Based Cancer Immunotherapeutic Vaccine Targeting HPV types 31/33/45/52/58
Gene & Nucleic acids HPV 31/33/45/52/58 positive Cervical Cancer or Head and Neck Squamous Cell Carcinoma (HNSCC) HPV 31/33/45/52/58 E6, E7 protein Lead Cellid Co., Ltd. RS-2026-25501687
55 Autophagy Inhibition-Based ULK1 Lead Discovery for Dual Targeting of Cancer Cells and TME in Pancreatic Cancer Therapy
Small molecules PDAC ULK1 Lead Cowellbiodigm RS-2025-25454972
56 Lead identification of TROP2 x PD-L1 x CD3 trispecific antibody using multi-body platform technology
Antibody NSCLC TROP2 x PD-L1 x CD3 Lead ARKGEN BioScions RS-2025-25450700
57 Lead generation of PD-1xVEGFxCTLA-4 trispecific antibody using UniStac platform
Antibody CRC, G/GEJ adenocarcinoma Cervical cancer PD-1, VEGF, CTLA-4 Lead Onegene Biotechnology RS-2025-25447260
58 Development of New Generation HPV Therapeutic Vaccine: Through Dual Targeting of Dendritic Cell TLR5/NLRC4 Pathways
rProtein High-risk HPV infection–induced cervical intraepithelial neoplasia (CIN) and early-stage cervical ca Dendritic cells (CD11c⁺ DCs) via dual activation of TLR5/NLRC4 pathways using HPV16/18/52/58/33/45 E Lead Chonnam National University R&BD Foundation RS-2025-25446859
59 Research on discovery of lead compounds to develop oral refractory cancer treatment targeting PTM(Post-translational modification) inhibition mechanism
Small molecules AML NMT Lead INNOVO Therapeutics RS-2025-25444455
60 Development of the first-in-class anti-cancer leading compounds blocking growth factor receptors based on the mechanism of target-protein degradation
TPD solid tumors expressing mutant growth factor receptors (GFRs) MYO1D/GFRs Lead Vaxcell-Bio RS-2025-25444375
61 Development of a Neuroendocrine Prostate Cancer Therapy by Targeting NF-κB Signaling via Neddylation inhibition
Small molecules Prostate cancer NEDD8 Lead Korea Research Institute of Chemical Technology RS-2025-02223190
62 Development of iPSC-derived NK cell therapy to induce chemotaxis of immune cells for liver cancer treatment
Cell therapies Liver cancer IL-7/CCL19 Lead TSD Life Sciences Inc. RS-2025-02213692
63 First-in-class pancreatic cancer therapy targeting both tumor metabolism and fibrosis for enhanced efficacy
Small molecules Pancreatic cancer NUAK1 Lead Korea Institute of Radiological and Medical Sciences RS-2025-02213330
64 Derivation of Trop2-Targeting Antibody-Cytokine Fusion Protein (anti-TROP2 ACFP) for Maximizing Anticancer Effects and Minimizing Side Effects
Antibody Solid cancer TROP2 Lead ABION. INC. RS-2025-02213236
65 Development of novel drug for anticancer RNA therapy using POC, which is effective in converting cold tumors into hot tumors
Gene & Nucleic acids Pancreatic cancer, SCC(Squamous cell carcinoma), Lung cancer CHI3L1 Lead Autotelic Bio Inc. RS-2025-02213057
66 Development of lead compounds as a SHP2 degrader for the treatment of KRAS mutant cancer
TPD KRAS (+) Pancreatic cancer/Solid cancer SHP2 Lead Elgen Therapeutic Inc. RS-2025-02202978
67 Development of Lead Therapeutic Antibody-Drug Conjugate Targeting CDCP1 for Pancreatic Cancer Treatment
Antibody CDCP1 (+)-Pancreatic cancer CDCP1 Lead Novelty Nobility Inc. RS-2025-02192979
68 Development of a Lead ADC Targeting LRRC15 for the Cancer Cells and Cancer-associated Fibroblasts
Antibody Osteosarcoma, Colon cancer, malignant melanoma LRRC15 Lead EdisBiotech. Co., Ltd. RS-2025-02183052
69 Development of a First-in-Class αPD-1/αVEGF/IL-2v Triple-Action Immuno-Oncology Therapeutic for Refractory Solid Tumors
rProtein Solid cancer αPD-1/αVEGF/IL-2v Lead MustBio RS-2025-02172980
70 Lead generation of HER3-ADC for the treatment of metastatic breast cancer
Antibody Metastatic breast cancer HER3 Lead IntoCell, Inc. RS-2024-00461865
71 Identification of Lead Candidate for PD-L1/*** Bispecific Antibody
Antibody Solid cancer PD-L1 and *** Lead GI Innovation Inc. RS-2024-00461392
72 Lead generation of intramolecular glue stabilizer targeting CBL-B as a treatment of colorectal cancer
TPD Colorectal Cancer (MSI-H/dMMR) CBL-B Lead IMMUSE Therapeutics RS-2024-00460474
73 Identification of estrogen receptor-degrading autophagytethering chimera (ATTEC) lead compounds for treating patients with ER-positive breast cancer
TPD Breast cancer (ER-positive) Estrogen Receptor Lead Korea Research Institute of Chemical Technology RS-2024-00459720
74 Development of Lead Compound of Personalized Circular mRNA Therapeutic Cancer Vaccine for the treatment of triple-negative breast cancer ONCOLOGY
Gene & Nucleic acids TNBC Tumor specific neoantigens predicted from deep learning platform technology Lead PENTAMEDIX CO., LTD. RS-2024-00443388
75 Lead generation of a first-in-class CD171 ADC against solid tumors
Antibody Solid tumor CD171 Lead APITBIO, Inc. RS-2024-00338745
76 Development of novel chemical immune checkpoint inhibitors by targeting CMTM6/PD-L1 axis in the tumor immune microenvironment for lung cancer immunotherapy
Small molecules Lung cancer, Solid cancer CMTM6 Lead Kangwon National University RS-2024-00338105
77 Derivation of new modality ‘Next Generation TPD’ leading materials targeting new target SOX2
Gene & Nucleic acids NSCLC, SCLC SOX2 Lead EPD Biotherapeutics Inc. RS-2024-00337873
78 Development of Innovative Gene Therapy Candidate for Hepatocellular Carcinoma Targeting High-Risk Dual-Specific Protein Phosphatase
Gene & Nucleic acids Hepatocellular Carcinoma CR-P1 Lead CUROGEN Technology RS-2024-00337392
79 Discovery of Small-Molecule Immunotherapeutics Dual-Targeting TAM and Treg in the Tumor Microenvironment
Small molecules Cancers(NSCLC, melanoma) with high tumor mutational burden CSF1R, PI3Kδ Lead Chung-Ang University/College of Pharmacy RS-2024-00337284
80 Development of a selective Discoidin Domain Receptor 1 (DDR1) inhibitor with first-in-class novel targets in multiple KRAS G12X-mutant malignant lung and pancreatic cancers
Small molecules KRAS G12X-mutant cancer DDR1 Lead CUREVERSE INC. RS-2024-00336018
81 Development of IKZF2 molecular glue degrader
TPD Solid tumor (NSCLC, Melanoma, TNBC) IKZF2 Lead Korea Reserch Institute Of Chemical Technology(KRICT) RS-2024-00332418
82 Development of first-in-class small molecule inhibitor targeting novel transcriptional regulator for cancer immunotherapy
Small molecules Solid tumor(ovarian, colorectal, melanoma, etc.) Novel transcriptional regulator function in both cancer and immune cells Lead SAMJIN PHARM.CO.,LTD. RS-2024-00332412
83 Discovery of AR-targeting ATTEC compounds for treating prostate cancer
TPD Castration-resistant prostate cancer Androgen receptor Lead Korea Reserch Institute Of Chemical Technology(KRICT) RS-2024-00332392
84 Development of a CD33.targeted lead antibody for the treatment of AML based on a novel innovative antibody platform technology
Antibody Cancer CD33 Lead Centenaire Biosciences RS-2023-00283660
85 Development of SIRT7 inhibitors for the treatment of unresectable hepatocellular carcinoma
Small molecules Cancer SIRT7 Lead Korea Reserch Institute Of Chemical Technology(KRICT) RS-2023-00283539
86 Novel bispecific antibodies development for Metastatic CastrationResistant Prostate Cancer
Antibody Cancer PSMA/CD137 Lead Ab Clon Inc. RS-2023-00283056
87 Development of third-generation antibody-drug conjugate linker technology capable of site-selectively conjugating payloads without antibody modification
Small molecules Gastric/GEJ AbClickⓇPro Lead AbTis Co., Ltd. RS-2023-00259367
88 Development of small molecule targeting FoxM1 for the treatment of colorectal cancer
Small molecules Solid Cancer FoxM1 Lead Korea Research Institute of Chemical Technology(KRICT) RS-2023-00258901
89
Small molecules Solid Cancer TLS Lead D5 Therapeutics RS-2023-00258885
90 Development of antibody against specific target expressed in the tumor microenvironment
Antibody Cancer HGF Lead Seoul National University RS-2023-00258823
91 Development of a new Topoisomerase I inhibitor based on a Kamtotesin derivative that can be used as an ADC payload
Small molecules Solid Tumor Topoisomerase I Lead Pinotbio, Inc. RS-2023-00258783
92 Development of a gene therapy for ovarian cancer using bispecific shRNA and antibody escaping oncolytic adenovirus
Gene & Nucleic acids Ovarian cancer c-Myc, BCL2 Lead Curigin Co., Ltd. RS-2023-00219308
93 Development of novel lead compounds inducing integrated stress response through HRI activation for the treatment of hematologic malignancies
Small molecules polycythemia vera HRI Lead NexThera Co., Ltd. RS-2023-00218778
94 First-in-Class FLT3 Degrader Discovery Using PROTACs and Chemoproteomics
TPD Acute myeloid leukemia, AML FLT3 Lead Yonsei University Industry-University Cooperation Foundation RS-2023-00218195
95 Developing Lead compound of AURKA Degrader for a potential anti-cancer therapy
TPD Cancer AURKA Lead UPPthera, Inc. RS-2023-00217986
96 Generation of the lead antibody targeting APP, a novel immuno-oncology target
Antibody Solid cancer APP Lead Genome & Company RS-2023-00217717
97 Development of a lead compound for anti-cancer drug using immunoactive attenuated Salmonella
Other-Bio. Solid Tumor FlaB, ClyA Lead CNCure biotech Inc. RS-2022-00167101
98 Development of a Novel Immunotherapeutics with Tumor-associated Macrophage(TAM) Suppression Mechanism
Antibody NSCLC CHI3L1 Lead Senelix RS-2022-00166446
99 Derivation of lead substance for colorectal cancer treatment of Repebody-drug conjugate with EGFR overexpression tumor-specific selective effect
rProtein Solid Tumor (EGFR overexpression) EGFR Lead ProEn Therapeutics RS-2022-00166310
100 Development of 19S RP UCHL5 inhibitors for the treatment of relapsed and refractory multiple myeloma
Small molecules Multiple Myeloma 19S RP UCHL5 Lead Korea Research Institute of Bioscience and Biotechnology RS-2022-00166286
101 A study on the leading optimization for cancer immunotherapy of regulatory T cell suppression/depletion mechanism using CD25-ApDC (CD25 aptamer-drug-conjugate)
Gene & Nucleic acids Solid Tumor CD25 Lead APTAMER Sciences RS-2022-00166270
102 Development of first-in-class endoglin-targeted CAR-NK and its application for inducing immune-friendly microenvironment
Cell therapies Relapsed and Refractory Pancreatic cancer Endoglin Lead Korea Institute of Science and Technology RS-2022-00166088
103 Development for immunotherapeutics targeting tumor-associated macrophages
Antibody Solid Tumor TREM2 Lead AimedBio Inc RS-2022-00166068
104 Discovery of novel PIP5K1a inhibitors as lead compounds for mCRPC therapy
Small molecules Prostate cancer PIP5K1α Lead TSD Life Sciences RS-2022-00165973
105 Development of a novel HPK1/MLK3 dual inhibitor, an immuno-oncology agent for MLK3-specific solid tumors
Small molecules Brain cancer, Lung cancer HPK1/MLK3 Lead MD Biolab RS-2022-00165566
106 Development of **** inhibitor for immuno-metabolic modulator
Small molecules Colorectal cancer GCN2 Lead 1st Biotherapeutics, Inc RS-2022-00165544
107 Discovery of novel TTK (MPS1) inhibitors for the TNBC treatment
Small molecules TNBC TTK Lead Korea Research Institute of Chemical Technology HN22C0694
108 Development of an implantable anticancer drug for prevention of local tumor recurrence and eradication of existing metastases after tumor resection of triple-negative breast cancer(TNBC)
Gene & Nucleic acids TNBC Nucleolin Lead Interoligo HN22C0585
109 Development of a treatment for refractory solid tumor targeting activated stellate cells
rProtein Solid tumor retinoid Lead Senelix HN22C0554
110 Discovery and development of novel ULK1 inhibitor as a therapeutic drug for RAS-mutated cancers
Small molecules Colorectal cancer, Lung cancer, Pancreatic cancer ULK1 Lead TXINNO Bioscience Inc HN22C0244
111 Development of first-in class MASTL-targeted drug in triple-negative breast cancer
Small molecules Breast Cancer MASTL Lead Korea Institute of Radiological & Medical Sciences HN22C0173
112 Discovery of small molecular G9a inhibitor leads in advanced solid tumor: tumor growth inhibition and anti-cancer immunity activation
Small molecules Solid Tumor G9a Lead Asan Medical Center HN22C0033
113 Development of humanized antibody for lung cancer treatment targeting DDOST protein
Antibody Lung cancer DDOST Lead Hanyang University HN21C1351
114 Identification of leading substances for the treatment of esophageal cancer and breast cancer based on PTK7-neutralizing humanized antibodies
Antibody Esophageal squamous cell carcinoma, TNBC, PTK7 expression cancer PTK7 Lead Yonsei University HN21C1214
115 Lead Generation of DLL3-ADC for the Treatment of Small Cell Lung Cancer
Antibody Rare cancer DLL3 Lead IntoCell HN21C1082
116 A small molecule inhibitor of the ubiquitin activating enzyme for regulating p53 in lung cancer
Small molecules Lung cancer p53 or USE1 Lead Korea Research Institute of Chemical Technology HN21C1078
117 Development of HMGCLL1 inhibitory small molecule CML therapeutic anticancer drug
Small molecules AML, CML HMGCLL1 Lead Samsung Medical Center HN21C0954
118 Discovery of lead compounds for the development of triple negative breast cancer treatments through HDAC6/8 dual inhibition
Small molecules TNBC HDAC6/8 Lead Sookmyung Women’s University HN21C0952
119 Tumor Targeting Liposomal Formulation of Cathepsin B-specific Doxorubicin Prodrug for Drug Resistant Cancer Treatment
Others-Synth. Colerectal cancer, Breast cancer, Ovarian cancer, Pancreatic cancer Cathepsin B Lead Ewha Womans University HN21C0349
120 Development and optimization of lead CD5 CAR-NK for T cell malignancies
Cell therapies Blood Cancer CD5 Lead Korea Research Institute of Bioscience and Biotechnology HN21C0117
121 Development of lead antibodies targeting an immune- checkpoint inhibitor refractory factor for metastatic non-small cell lung carcinoma
Antibody Lung cancer NSN-001 Lead NEX-I, Inc HN21C1323
122 Development of a lead compound targeting USP21 for inhibiting cancer metastasis
Small molecules Colerectal cancer USP21 Lead Daegu Gyeongbuk Medical Innovation Foundation HN21C1210
123 Derivation of lead compound as TRIB2 inhibitor for development of triple negative breast cancer therapy
Small molecules Breast cancer TRIB2 Lead GENESEN Co., Ltd. HN21C1201
124 Lead identification of GLS1 target via allosteric inhibition
Small molecules Solid Tumor GLS1 Lead Korea Research Institute of Chemical Technology HN21C1180
125 Efficacy and safety on anti-cancer drug candidate of immune-checkpoint protein and cytokine fused platform
rProtein Cancer IL-21, PD-1 Lead BIOnSYSTEMS HN21C1099
126 Lead selection of PD-L1xCD3 targeted immuno-oncology (MB101) applying a novel bispecific antibody platform technology
Antibody Solid Tumor PD-L1, CD3 Lead MustBio Inc HN21C0985
127 Identification of next-generation EGFR degraders to treat Non-Small Cell Lung Cancer (NSCLC) patients
TPD NSCLC EGFR mutation Lead Cyrus Therapeutics HN21C0965
128 Establishment of leading compounds to overcome tumor heterogeneity and anticancer drug resistance of pancreatic cancer and liver cancer by using oncolytic adenovirus/mesenchymal stem cell complex capable of both enhanced tumor targeting and virus replication
Gene & Nucleic acids Pancreatic cancer, Liver cancer TGFβ1, HSP27 Lead Yonsei University HN21C0960
129 GCM-101: Development of cancer-immunotherapy with oncolytic herpes simplex virus (oHSV) in ovarian cancer
Gene & Nucleic acids Ovary cancer EpCAM Lead GenCellMed HN21C0935
130 Lead development study on exosomes with anticancer potential armed with FAF1, a multifunctional tumor suppressor and a genuine exosome cargo
Other-Bio. Pancreatic cancer, Liver cancer FAF1 Lead ChungNam National University HN21C0048
131 Development of CD19-Targeted CAR-X Combination Therapy Candidates for Solid Tumors
Gene & Nucleic acids TNBC CD19 Candidate artiCure RS-2026-25503880
132 Development of a First-in-Class Nanodrug (DC-MT) Candidate for Colorectal Cancer Radiotherapy
Others-Synth. Concurrent Chemoradiotherapy for solid tumor Hypoxic tumor microenvironment cancer Candidate Dr.Cure.,Co.,LTD. RS-2026-25503777
133 Preclinical Discovery of Pearl-101, a First-in-Class Poly(ADP-ribose)-Stabilizing Peptide Therapeutic for BRCA-Mutant Therapy-Resistant Breast Cancer
rProtein Breast Cancer Poly(ADP-ribose) Candidate Pearlsinmires Co., Ltd. RS-2026-25503204
134 Pre-clinical Safety and Efficacy Validation of GB2Ab, an ‘Induced-fit’ GFRAL Receptor Antagonist, for Cancer Cachexia Treatment and Potentiating Immuno-Oncology Response
Antibody Cancer-associated cachexia (CAC) GFRAL (GDNF Family Receptor Alpha-Like) Candidate Thor therapeutics Inc. RS-2026-25503136
135 Development of a Solid Tumor Therapeutic Candidate Using a T-SphaeraTM-PD-L1 x VEGF Multi-specific Therapeutics (TSMT-01)
rProtein Solid Tumors (NSCLC, TNBC, etc.) PD-L1 and VEGF (multivalency, high avidity) Candidate CELLemedy Inc. RS-2026-25502818
136 Development of mRNA immuno-oncology therapeutic candidates leveraging an AI-based tumor-targeted fusion cytokine design platform
Gene & Nucleic acids HNSCC **** Candidate CHA Vaccine Institute RS-2026-25501908
137 Development of a Novel ADC Candidate Targeting ITGB4 through Lead Optimization and Initiation of Preclinical Development
Antibody Solid Tumor ITGB4 Candidate Genome & Company RS-2026-25501836
138 Development of an AI-Based PD1-IL18v Bispecifc candidate with immune cell-specific activity in the tumor microenvironment.
rProtein Patients with primary or acquired resistance to PD-1 inhibitors PD-1, IL-18 Candidate Galux Inc. RS-2026-25501722
139 Discovery of anticancer candidate targeting peroxiredoxin 2-deficient Triple-Negative Breast Cancer for personalized treatment
Small molecules TNBC PRDX2 Candidate VasThera Co., Ltd. RS-2025-25454944
140 Development of an Optimized Radiopharmaceutical for Targeted Therapy of Metastatic Malignant Melanoma
RPT Melanoma Melanin Candidate CNCure Co., Ltd. RS-2025-25454797
141 Development of Next-Generation HER2-Targeted ADC Candidates Employing NAMPT Inhibitor Payloads to Overcome Limitations of Current Therapies
Antibody Solid tumor NAMPT Candidate Samjin Pharmaceutical RS-2025-25454767
142 Development of FLT3 Degrader Candidate Targeting Drug-resistant Mutants
TPD Acute myeloid leukemia (AML) FLT3 Candidate MagicBullet Therapeutics RS-2025-25450363
143 Development of an ADC therapeutic candidate targeting the novel antigen *** for the treatment of solid tumors
Antibody HCC & SCLC *** Candidate Boostimmune RS-2025-25445446
144 Establishing the Foundation for Nonclinical Entry of VLP-Peptide-Based Pancreatic Cancer Immunotherapy Vaccine Candidate
rProtein Pancreatic Cancer and Prevention of Its Metastasis hTERT Candidate POSVAX Co., LTD. RS-2025-25444576
145 Discovery of Anti-Cancer Drug Candidates Using Molecular Glue-Based GSPT1 Degraders
TPD Multiple myeloma Lung cancer Prostate cancer GSPT1 Candidate Protier Biotech RS-2025-25444435
146 Development of a Candidate Therapeutic Antibody Targeting CTHRC1 for the Treatment of Triple-Negative Breast Cancer
Antibody TNBC CTHRC1 Candidate Prestige Biopharma IDC RS-2025-25444331
147 Preclinical Development of an Aptamer-Based Anti-Cancer Drug Targeting ALCAM
Gene & Nucleic acids Ovarian cancer ALCAM (CD166) Candidate HiCellTech Inc. RS-2025-02223684
148 Development of EGFR-targeting ADC candidate for the treatment of metastatic (late-stage) colorectal cancer
rProtein Colon cancer EGFR Candidate ProEn Therapeutics Inc. RS-2025-02223464
149 Development of TME responding Probody CD3xCEACAM5 T-cell engager
Antibody Solid cancer CD3, CEACAM5 Candidate DAAN Biotherapeutics, Inc. RS-2025-02223296
150 Development of novel small molecule anticancer drugs targeting USP1
Small molecules TNBC, Ovarian cancer (BRCA mut) USP1 Candidate HYUNDAI PHARM RS-2025-02223126
151 Development of a second-generation c-MET inhibitor to overcome acquired resistance to first-generation c-MET inhibitors
Small molecules NSCLC cMET Candidate CMG Pharmaceutical Co.Ltd RS-2025-02213745
152 Development of novel neoadjuvant therapy for triple negative breast cancer (TNBC)
Gene & Nucleic acids Solid cancer Type I interferon Candidate NA Vaccine Institute RS-2025-02213626
153 Preclinical research and development of AD0126 as a selective USP1 inhibitor
Small molecules HRD (+) cancer (TNBC, Ovarian cancer), HRP solid cancer (NSCLC) USP1 Candidate Avelos Therapeutics, Inc. RS-2025-02213433
154 Identification of Molecular Glue drug Candidates for PLK1 Degradation
TPD TNBC PLK1 Candidate AevisBio, Inc RS-2025-02212974
155 Development of pan-KRAS Inhibitor Candidates for KRAS-Mutant Cancer Patients
Small molecules KRAS (+) solid cancer KRAS Candidate Idience Co., Ltd. RS-2025-02183021
156 Identification of a CDK7 inhibitor as a development candidate for HR+ HER2- metastatic breast cancer patients with resistance to CDK4/6 inhibitors
Small molecules Breast cancer (HR+ HER2-) CDK7 Candidate Cyrus Therapeutics RS-2024-00463231
157 Development of mutant PI3Kalpha chaperone-mediated degrader candidate
TPD Breast cancer PI3Kα-chaperone Candidate MagicBullet Therapeutics RS-2024-00462810
158 Discovery of novel anti-CD33 antibody-enabled GSPT1 degraders for treatment of relapsed and refractory AML
Antibody Acute myeloid leukemia GSPT1 Candidate Therapex Co., Ltd. RS-2024-00443425
159 A novel monobody & scFv-based CAR-T for solid cancer
Cell therapies Solid tumor (Ovarian Cancer) EphA2, PD-L1 Candidate VAXCELL-BIO CO., LTD RS-2024-00341192
160 A Study on the Development of USP1 inhibitor candidate as a New Synthetic Lethality Target for the Treatment of BRCA (-) and HRD (+) Cancer
Small molecules Cancer (BRCA Mutant) USP1 Candidate AIGEN Sciences RS-2024-00338363
161 Lead Optimization of Solid tumor-targeting MUC1-CAR-T Cell Therapy Candidate Utilizing AviCLIP-CAR Technology
Cell therapies MUC1 positive solid cancer MUC1 Candidate TiCARos. Inc RS-2024-00337759
162 Study to derive a final lead candidate of TCR-T cell therapy for the treatment of EGFR L858R mutant lung cancer patients
Cell therapies EGFR L858R mutant lung cancer pMHC Candidate DAAN Biotherapeutics RS-2024-00336489
163 Develop Anti-Cancer Therapeutics for HER2 low Gastric Cancers by Combining Targeting Peptide and NanoCarrier
Other-Bio. HER2 low Gastric Cancer HER2 Candidate KMD Bio Ltd RS-2024-00333872
164 Development of the candidate for Standard Treatment-Resistant/Refractory Prostate Cancer through direct inhibition of XBP1s, a Mediator of ER stress
Small molecules Metastatic Castration Resistant Prostate Cancer XBP1s Candidate JW C&C Research Laboratories RS-2024-00333115
165 Study on the deriving of oHSV-1 candidate for an immunotherapeutic targeting to the ovarian cancer
Gene & Nucleic acids Ovarian cancer Epithelial Cell Adhesion Molecule (EpCAM) Candidate Gencellmed Inc. RS-2024-00332252
166 Identification of small molecule PKMYT1 inhibitor candidates for development of advanced solid tumor treatment
Small molecules Solid tumor PKMYT1 Candidate Voronoi Inc. RS-2023-00283890
167 Development of universal iPSC.NK (induced pluripotent stem cellderived NK cell therapy) with higher ability of immune evasion and persistence for the treatment of solid cancer
Cell therapies Liver cancer IL.15RF, HLA.G Candidate Therabest Co., Ltd RS-2023-00283732
168 A Study on the Development of First.in.class Myc Inhibitor Candidate for the Treatment of Solid Tumor and Hematologic Cancer
Small molecules Cancer Myc Candidate Incurix Co., Ltd. RS-2023-00283511
169 Development of an NMC Therapeutic Candidate Using a BRD4.NUT Degrader
Small molecules NUT Midline Carcinoma BRD4.NUT Candidate Innocure Therapeutics Inc. RS-2023-00282701
170 Development of siRNA therapeutics to target KRAS/G12D.mutant pancreatic cancer
Gene & Nucleic acids Pancreatic cancer KRAS/G12D Candidate Exollence Co., Ltd. RS-2023-00282594
171 Development of novel small molecule anticancer drugs targeting SMARCA2
Small molecules NSCLC, Melanoma SMARCA2/4 Candidate Hyundai Pharm RS-2023-00259457
172 The generation of candidate for Relapsed and Refractory Acute Myeloid Leukemia to FLT3 inhibitors via direct STAT5/3 inhibition
Small molecules Acute Myeloid Leukemia STAT3/5 Candidate JW C&C Research Laboratories RS-2023-00258859
173 Direct inhibitor of AR/AR.V7 DNA binding for castration.resistant prostate cancer
Small molecules Castration.resistant prostate cancer Androgen receptor (AR) and AR.V7 Candidate Incurix RS-2023-00258594
174 Candidate selection of a first.in.class RNA therapeuticfor the treatment of BRAF mutant pediatric brain tumors
Gene & Nucleic acids Pediatric brain tumor BRAF Candidate Sovargen RS-2023-00258484
175 Lead optimization and candidate selection of PD.L1 small molecule inhibitor for non.clinical study
Small molecules Solid Cancer PD.1/PD.L1 Candidate Ilab RS-2023-00258167
176 Efficacy and safety evaluation of the peptide candidate CBT-001-839 for CAIX-targeted cancer diagnostic and therapeutic radiopharmaceuticals
rProtein ccRCC CAIX Candidate C-BIOMEX RS-2023-00218641
177 Derivation of First-in-Class therapeutic antibody candidate for the treatment of claudin-3 overexpressing solid cancers
Antibody CLDN3hi solid cancer CLDN3 Candidate Abion, Inc. RS-2023-00218182
178 Discovery of pre-clinical candidates for inhibition of SOS1 for the treatment of KRAS mutated cancers
Small molecules KRAS-mutated solid cancer(Pancreatic, Lung, Colon cancer) SOS1 Candidate Jeil Pharmaceutical RS-2023-00217674
179 Candidate development of anti-TCTP neutralizing candidate (BIO101) for the treatment of solid tumors
Antibody Solid Cancer TCTP Candidate Boostimmune, Inc. RS-2023-00217478
180 Efficacy evaluation of optimized CAR-T therapy against refractory epithelial ovarian cancer
Cell therapies Ovarian cancer 메소텔린 Candidate CellenGene RS-2023-00217215
181 Development of next-generation allosteric EGFR inhibitor for non-small cell lung cancer treatment
Small molecules NSCLC EGFR Candidate HK inno.N RS-2023-00217095
182 Development of therapeutics for acute myeloid leukemia with CK1alpha selective molecular degrader
TPD AML CK1α Candidate Pin Therapeutics RS-2022-00166852
183 Development of next-generation cancer immunotherapy via FAP-targeted IL-12 attenuation-based TMEkineTM
rProtein Solid Tumor FAP, IL-12 Candidate KANAPH Therapeutics RS-2022-00166851
184 Development of HER2-positive cancer treatment candidate through interferon-beta immunocytokine efficacy evaluation and production process research
rProtein HER2+ tumor IFN-β Candidate Genopharm Inc. RS-2022-00166539
185 Candidate development of individualized cancer vaccine for the non-Hodgkin Lymphoma
Other-Bio. Non-Hodgkin lymphoma Non-Hodgkin Lymphoma Candidate Progeneer RS-2022-00166284
186 Development of personalized cancer vaccine against advanced stage lung cancer patients with immunotherapy resistance
rProtein Lung cancer Tumor specific neoantigens predicted from deep learning platform technology Candidate Penta Medix RS-2022-00166187
187 Development of a non-clinical candidate for colorectal cancer treatment RACE-111 (EGFRX4-1BB) bispecific antibody
Antibody Colorectal cancer EGFR, 4-1BB Candidate CTCELLS RS-2022-00166009
188 Secured ex vivo gene therapy candidate for the treatment of solid tumor
Cell therapies Glioblastoma Cytosine Deaminase Candidate CELL & BRAIN Co., Ltd RS-2022-00165974
189 Anti-DX2 chemical drug to control KRAS-driven cancer
Small molecules Colorectal cancer (KRAS mutation) KRAS Candidate Zymedi HN22C0682
190 Development of a combination therapy for colorectal cancer using attenuated Salmonella and anti-PD-L1 antibody
Other-Bio. Colorectal cancer Colorectal cancer (late stage) patients Candidate CNCure biotech Inc. HN22C0637
191 Polo-like kinase 1(PLK1) degradation using the N-degron pathway in PROTACs and its application of developing to non-small cell lung cancer(NSCLC) target drug candidates
TPD NSCLC PLK1 Candidate DANDI CURE HN22C0563
192 ARTI 101 : Oncospreading antitumor retroviral vectors
Gene & Nucleic acids Glioblastoma Cytosine Deaminase Candidate ArtiCure HN22C0469
193 Development of immuno-cancer antibodies that improves single and/or combination anti-cancer efficacy by improving immune suppressive tumor microenvironments
Antibody Solid Tumor B7-H3/TGF-β Candidate Theranotics HN22C0442
194 Development of personalized solid cancer therapy with neoantigen targeted TCR-T cells
Cell therapies Solid Tumor Neoantigen Candidate Neogen TC HN22C0269
195 Development of cancer cachexia treatment using anti-GFRAL antibody
Antibody Cancer Cachexia GFRAL Candidate TroyY HN22C0147
196 Development of SHP2 allosteric inhibitor with dual mechanisms of targeting the RAS pathway and enhancing anti-tumor immunity
Small molecules Nsclc, Colerectal Cancer, Head and Neck Cancer, Esophageal Cancer SHP2 Candidate KANAPH Therapeutics HN22C0066
197 Candidate development of PD-L1xIL-2v immuno-oncology (MB201) applying a novel bispecific antibody platform technology
Antibody Solid Tumor PD-L1, IL-2 Candidate MustBio Inc HN22C0050
198 Development of anti-HLA-G/CD3 T-cell engaging bispecific antibody for the treatment of CRC patients
Antibody Colorectal cancer HLA-G, CD3 Candidate Y-Biologics HN21C1337
199 Development of peptide vaccine against the pancreatic or lung cancers with KRAS mutation
rProtein Pancreatic cancer, Lung cancer KRAS mutant Candidate NA Vaccine Institute HN21C1308
200 Identification of Preclinical Small Molecule Candidate which induces STING protein expression by inhibiting TRIM29-mediated STING Ubiquitination
Small molecules Solid Tumor TRIM29 Candidate SPARK Biopharma, Inc. HN21C1026
201 Discovery of drug candidate for HER2 positive Breast cancer treatment using HER2 targeted Small molecule with high brain permeability
Small molecules Breast cancer HER2 Candidate B2SBio Inc. HN21C0826
202 Novel Non-Covalent BTK Inhibitor, Exhibits Potent Anti-tumor Activity in B-Cell Lymphoma
Small molecules CML BTK (C481S) Candidate Medytox HN21C0823
203 Development of a novel ADC for the treatment of glioblastoma
Antibody Glioblastoma FGFR3 Candidate Aimed Bio Inc. HN21C0803
204 Development of candidate compounds for 
Probe & Catch CAR-T cells targeting 
CD40-positive hematologic tumors
Cell therapies Blood tumor CD40 Candidate TiCARos Inc HN21C0764
205 Next-generation anti-TIGIT antibody (7043H1E) with enhanced Fc function
Antibody Solid Tumor TIGIT Candidate HanAll BioPharma HN21C0596
BACK